Psychedelic stocks are well off of their 2020 highs. But they are even further from their 2020 lows. Opportunity knocks.
Psychedelic stocks are well off of their 2020 highs. But they are even further from their 2020 lows. Opportunity knocks.
MINDCURE's new Director is a veteran of capital markets.
MINDCURE's R&D on traumatic brain injury (TBI) targets the LARGEST individual market for psychedelic drugs.
MINDCURE's first line of mushroom-based nootropics now available for sale.
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
MINDCURE adds bioinformatics to its drug development platform.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now